The potential antidepressant effect of antidiabetic agents: New insights from a pharmacovigilance study based on data from the reporting system databases FAERS and VigiBase

Growing evidence supports a bidirectional association between diabetes and depression; promising but limited and conflicting data from human studies support the intriguing possibility that antidiabetic agents may be used to relieve effectively depressive symptoms in diabetic patients. We investigate...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in pharmacology 2023-02, Vol.14, p.1128387-1128387
Main Authors: Battini, Vera, Van Manen, Robbert P, Gringeri, Michele, Mosini, Giulia, Guarnieri, Greta, Bombelli, Anna, Pozzi, Marco, Nobile, Maria, Radice, Sonia, Clementi, Emilio, Carnovale, Carla
Format: Article
Language:English
Subjects:
antidiabetic agents
depression
diabetes
drug repurposing
Pharmacology
pharmacovigilance
real-world data
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Growing evidence supports a bidirectional association between diabetes and depression; promising but limited and conflicting data from human studies support the intriguing possibility that antidiabetic agents may be used to relieve effectively depressive symptoms in diabetic patients. We investigated the potential antidepressant effects of antidiabetic drugs in a high-scale population data from the two most important pharmacovigilance databases, , the FDA Adverse Event Reporting System (FAERS) and the VigiBase. From the two primary cohorts of patients treated with antidepressants retrieved from FDA Adverse Event Reporting System and VigiBase we identified (depressed patients experiencing therapy failure) and (depressed patients experiencing any other adverse event). We then calculated the Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Empirical Bayes Geometric Mean (EBGM), and Empirical Bayes Regression-Adjusted Mean (ERAM) for s in relation with the concurrent exposure to at least one of the following antidiabetic agent: A10BA Biguanides; A10BB Sulfonylureas; A10BG Thiazolidinediones; A10BH DPP4-inhibitors; A10BJ GLP-1 analogues; A10BK SGLT2 inhibitors ( ., those agents for which preliminary evidence from literature supports our pharmacological hypothesis). For GLP-1 analogues, all the disproportionality scores showed values
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2023.1128387